Who has invested in BioVersys?

GSK are named among the investors backing BioVersys.

BioVersys Funding: $70M Raised, Series C (2024)

BioVersys funding overview

BioVersys is based in Zurich, Switzerland. BioVersys has raised $70M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series C announced in May 2024. The round record for BioVersys runs through 2024; nothing later has been disclosed. Investors on record include GSK.

BioVersys at a glance

Total raised: $70M
Latest round: Series C
Latest round date: May 2024
Headquarters: Zurich, Switzerland
Notable investors: GSK

Frequently asked about BioVersys funding

How much has BioVersys raised?: BioVersys has raised $70M in total disclosed funding across the rounds on record.
Who has invested in BioVersys?: GSK are named among the investors backing BioVersys.
What was the latest BioVersys funding round?: The most recent disclosed round is a Series C, announced in May 2024.
Where is BioVersys based?: BioVersys is based in Zurich, Switzerland.
When did BioVersys last raise?: The last disclosed BioVersys round closed in May 2024 at Series C.

Round data for BioVersys is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the companies in Zurich and backer lists below.

BioVersys Funding: $70M Raised, Series C (2024)

BioVersys funding overview

BioVersys at a glance

Frequently asked about BioVersys funding

Companies related to BioVersys (23)

Browse related funding lists (3)